Victoria Levesque

1.6k total citations · 1 hit paper
11 papers, 1.1k citations indexed

About

Victoria Levesque is a scholar working on Pathology and Forensic Medicine, Cardiology and Cardiovascular Medicine and Rheumatology. According to data from OpenAlex, Victoria Levesque has authored 11 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 3 papers in Cardiology and Cardiovascular Medicine and 3 papers in Rheumatology. Recurrent topics in Victoria Levesque's work include Multiple Sclerosis Research Studies (6 papers), Erythropoietin and Anemia Treatment (3 papers) and Systemic Lupus Erythematosus Research (3 papers). Victoria Levesque is often cited by papers focused on Multiple Sclerosis Research Studies (6 papers), Erythropoietin and Anemia Treatment (3 papers) and Systemic Lupus Erythematosus Research (3 papers). Victoria Levesque collaborates with scholars based in Switzerland, Spain and United States. Victoria Levesque's co-authors include Claudio Mori, Georg Ertl, Luigi Tavazzi, Bernard Roubert, Mareev VIu, Dirk J. van Veldhuisen, Theresa A. McDonagh, Stefan D. Anker, Alexander Parkhomenko and Gerasimos Filippatos and has published in prestigious journals such as Neurology, European Heart Journal and Human Brain Mapping.

In The Last Decade

Victoria Levesque

11 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency

2014 821 citations Piotr Ponikowski, Dirk J. van Veldhuisen et al. European Heart Journal profile →

Peers

Victoria Levesque

HEMAT

CCM

GENET

PFM

NEPHR

Gábor Széplaki Hungary

Luciano Moretti Italy

Kan Saito Japan

Jim Thom Australia

Yutaka Kagaya Japan

Deddo Mörtl Austria

Hiroe Niwano Japan

M Balletta Italy

Ewa Koc‐Żórawska Poland

Gábor Széplaki Hungary

Victoria Levesque

203 ×0.3

HEMAT

604 ×1.2

CCM

441 ×2.3

GENET

168 ×1.2

PFM

39 ×0.3

NEPHR

Citations per year, relative to Victoria Levesque Victoria Levesque (= 1×) peers Gábor Széplaki

Countries citing papers authored by Victoria Levesque

Since Specialization

Citations

This map shows the geographic impact of Victoria Levesque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Levesque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Levesque more than expected).

Fields of papers citing papers by Victoria Levesque

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Levesque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Levesque. The network helps show where Victoria Levesque may publish in the future.

Co-authorship network of co-authors of Victoria Levesque

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Levesque. A scholar is included among the top collaborators of Victoria Levesque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Levesque. Victoria Levesque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Hauser, Stephen L., Ludwig Kappos, Douglas L. Arnold, et al.. (2020). Five years of ocrelizumab in relapsing multiple sclerosis. Neurology. 95(13). e1854–e1867. 106 indexed citations

O’Muircheartaigh, Jonathan, Irene M. Vavasour, Emil Ljungberg, et al.. (2019). Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis. Human Brain Mapping. 40(7). 2104–2116. 50 indexed citations

MacMillan, Erin L., Julia Schubert, Irene M. Vavasour, et al.. (2019). Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. Multiple Sclerosis Journal - Experimental Translational and Clinical. 5(4). 2454299920–2454299920. 8 indexed citations

Arnold, Douglas L., Ludwig Kappos, Stephen L. Hauser, et al.. (2018). Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 26. 265–265. 5 indexed citations

Arnold, Douglas L., Ludwig Kappos, Stephen L. Hauser, et al.. (2018). Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002). Neurology. 90(15_supplement). 2 indexed citations

Kolind, Shannon, Irene M. Vavasour, Lisa Tang, et al.. (2017). Advanced Myelin-related MRI Measures in Relapsing Multiple Sclerosis Patients treated with Ocrelizumab or Interferon Beta-1a Over 96 Weeks (P6.371). Neurology. 88(16_supplement). 3 indexed citations

Dall’Era, Maria, Victoria Levesque, Neil Solomons, Matt Truman, & David Wofsy. (2015). Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science & Medicine. 2(1). e000089–e000089. 39 indexed citations

Ponikowski, Piotr, Dirk J. van Veldhuisen, Josep Comín‐Colet, et al.. (2014). Rationale and Design of the CONFIRM-HF Study: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effects of Intravenous Ferric Carboxymaltose on Functional Capacity in Patients with Chronic Heart Failure and Iron Deficiency. ESC Heart Failure. 1(1). 52–58. 36 indexed citations

Ponikowski, Piotr, Dirk J. van Veldhuisen, Josep Comín‐Colet, et al.. (2014). Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 36(11). 657–668. 821 indexed citations breakdown →

10.

Ponikowski, Piotr, Dirk J. van Veldhuisen, Josep Comín‐Colet, et al.. (2014). Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure. n/a–n/a. 1 indexed citations

11.

Dall’Era, Maria, David K. Stone, Victoria Levesque, Miriam G. Cisternas, & David Wofsy. (2010). Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care & Research. 63(3). 351–357. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact